HCPLive

HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care to patients. The site covers a wide range of medical topics, including therapeutic approaches to primary biliary cholangitis (PBC), the impact of diet on public health, and emerging therapies for various conditions. The reporting is generally unbiased and free from conflicts of interest, with occasional contradictions in the articles. The site features breaking news, video interviews with physician experts, in-depth conference coverage, finance and practice management updates, insight and analysis from physician contributors.

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This news site is known for its high journalistic standards. It strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. It has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

  • HCPLive provides balanced and unbiased reporting on various medical topics.

Conflicts of Interest

100%

Examples:

  • There is no evidence of conflicts of interest affecting the reporting at HCPLive.

Contradictions

88%

Examples:

  • The information provided in the articles may occasionally contain contradictions or conflicting data, but these instances are rare and not a major concern.

Deceptions

100%

Examples:

  • The articles provided do not contain any deceptive practices or misleading information.

Recent Articles

  • New Drug Iqirvo Approved for Primary Biliary Cholangitis: A Look at Emerging Therapies and Unmet Needs

    New Drug Iqirvo Approved for Primary Biliary Cholangitis: A Look at Emerging Therapies and Unmet Needs

    Broke On: Friday, 21 June 2024 The FDA approved Iqirvo (elafibranor) for Primary Biliary Cholangitis (PBC) treatment, showing improvements in biochemical response compared to UDCA alone. Emerging therapies like next-generation PPAR agonists and Ileal bile acid transporter inhibitors (IBAT inhibitors) are promising, reducing cholestasis and improving cognitive impairment and fatigue. Experts emphasize the need for continued observation and validation through further studies.
  • New Drug Iqirvo Approved for Primary Biliary Cholangitis: A Look at Emerging Therapies and Unmet Needs

    New Drug Iqirvo Approved for Primary Biliary Cholangitis: A Look at Emerging Therapies and Unmet Needs

    Broke On: Friday, 21 June 2024 The FDA approved Iqirvo (elafibranor) for Primary Biliary Cholangitis (PBC) treatment, showing improvements in biochemical response compared to UDCA alone. Emerging therapies like next-generation PPAR agonists and Ileal bile acid transporter inhibitors (IBAT inhibitors) are promising, reducing cholestasis and improving cognitive impairment and fatigue. Experts emphasize the need for continued observation and validation through further studies.
  • New Drug Iqirvo Approved for Primary Biliary Cholangitis: A Look at Emerging Therapies and Unmet Needs

    New Drug Iqirvo Approved for Primary Biliary Cholangitis: A Look at Emerging Therapies and Unmet Needs

    Broke On: Friday, 21 June 2024 The FDA approved Iqirvo (elafibranor) for Primary Biliary Cholangitis (PBC) treatment, showing improvements in biochemical response compared to UDCA alone. Emerging therapies like next-generation PPAR agonists and Ileal bile acid transporter inhibitors (IBAT inhibitors) are promising, reducing cholestasis and improving cognitive impairment and fatigue. Experts emphasize the need for continued observation and validation through further studies.
  • New Drug Iqirvo Approved for Primary Biliary Cholangitis: A Look at Emerging Therapies and Unmet Needs

    New Drug Iqirvo Approved for Primary Biliary Cholangitis: A Look at Emerging Therapies and Unmet Needs

    Broke On: Friday, 21 June 2024 The FDA approved Iqirvo (elafibranor) for Primary Biliary Cholangitis (PBC) treatment, showing improvements in biochemical response compared to UDCA alone. Emerging therapies like next-generation PPAR agonists and Ileal bile acid transporter inhibitors (IBAT inhibitors) are promising, reducing cholestasis and improving cognitive impairment and fatigue. Experts emphasize the need for continued observation and validation through further studies.
  • US Diet Improving but Still Suboptimal for Over a Third of Adults: Study Highlights Persisting Disparities

    US Diet Improving but Still Suboptimal for Over a Third of Adults: Study Highlights Persisting Disparities

    Broke On: Monday, 17 June 2024 A Tufts University study published in Annals of Internal Medicine reveals that while the average US diet has improved from 1999 to 2020, over a third of adults still have poor diet quality. Disparities exist among demographics including income, age, and health insurance. The study found reductions in sugar intake and greater consumption of nuts, whole grains, poultry, cheese and eggs. However, disparities persist for socioeconomically vulnerable populations.
  • GLP-1 Receptor Agonists and Psychiatric Issues: Two Cases of Depression and Suicidal Ideation Linked to Semaglutide

    GLP-1 Receptor Agonists and Psychiatric Issues: Two Cases of Depression and Suicidal Ideation Linked to Semaglutide

    Broke On: Wednesday, 08 May 2024 Two case studies presented at the American Psychiatric Association annual meeting suggest a potential link between GLP-1 receptor agonists like semaglutide and psychiatric issues, including depression and suicidal ideation. The medication, which acts on the brain to modulate food intake and reward, has been associated with approximately 60 reported cases of suicidal ideation since 2018. Further research is needed to identify specific proteins or enzymes that may exacerbate psychological conditions and contribute to these risks.

  • Semaglutide and Sotagliflozin Show Promising Results for Type 2 Diabetes Patients

    Broke On: Friday, 03 November 2023 The majority of patients did not experience worsening of their diabetic retinopathy (DR) after initiating semaglutide (Ozempic) to treat their type 2 diabetes (T2D). Sotagliflozin, a dual SGLT1 and 2 inhibitor, has been found to provide kidney and heart benefits in patients with type 2 diabetes and chronic kidney disease. Over a median follow-up of 16 months, sotagliflozin reduced the risk of kidney-related complications by 38% and a cardiorenal composite outcome by 23%.